Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status.

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status.

Hsu, Jim; Annunziata, Joseph F; Burns, Ethan; Bernicker, Eric H; Olsen, Randall J; Thomas, Jessica S.

Afiliação

Hsu J; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Annunziata JF; Clinical Pathology Associates, Norton Healthcare, Louisville, KY, USA.
Burns E; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
Bernicker EH; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
Olsen RJ; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Thomas JS; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.

Clin Pathol ; 15: 2632010X221102054, 2022.

Article em En | MEDLINE | ID: mdl-35634237